Transient acid exposure increases sevelamer HCl phosphate binding

Journal of Pharmaceutical Sciences

Volumn 96, Issue 8, 2007, Pages 2154-2160

  Ross, Edward A ^a   Scott III, William E ^b   Odukale, Anika A ^b   Alba, Nicolas A ^b   Batich, Christopher D ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b University of Florida   (United States)

Author keywords

Adsorption; Hydration; Hydrogels; Polymer synthesis; Polymeric drugs

Indexed keywords

PHOSPHATE; SEVELAMER;

ARTICLE; BINDING AFFINITY; DRUG ADSORPTION; DRUG FORMULATION; DRUG UPTAKE; HYDROPHOBICITY; IMAGE ANALYSIS; IONIC STRENGTH; PH MEASUREMENT;

EID: 34548046206     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20914     Document Type: Article

References (13)

1. Chertow G, Burke SK, Dillon M, Slatopolsky E. 1999. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14:2907-2914.
2. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. 2000. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New Engl J Med 342:1478-1483.
3. National Kidney Foundation. 2003. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1-201.
4. Ross EA, Scott WE III, Odukale AA, Batich CD. 2004. Synthesis of molecularly imprinted polymers (MIPs) for phosphate binding [Abstract]. J Am Soc Nephrol 15:859A.
5. Ross EA, Scott WE III, Odukale AA, Batich CD. 2004. Acid exposure increases sevelamer HCl phosphate binding. [Abstract]. J Am Soc Nephrol 15:275A.
6. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E. 1999. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26.
7. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. 1999. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701.
8. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI. 1997. Effect of Renagel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant 12:961-964.
9. Batich CD, Yan J, Bucaria C, Elsabee M. 1993. Swelling behavior of pH-sensitive copolymers based on styrene and 4-(or 2-)vinylpyridine. Macromolecules 26:4675-4680.
10. Brannon-Peppas L, Peppas NA. 1991. Equilibrium swelling behavior of pH-sensitive hydrogels. Chem Eng Sci 46:715-722.
11. Siegel RA, Firestone BA. 1988. pH dependent equilibrium swelling of hydrophobic poly-electrolyte copolymer gels. Macromolecules 21:3254-3259.
12. Holmes-Farley SR, Mandeville WH III, Whitesides GM. 1997. Phosphate-binding polymers for oral administration. US patent #5,667,775.
13. Swearingen RA, Chen X, Petersen JS, Riley KS, Wang D, Zhorov E. 2002. Determination of the binding parameter constants of Renagel® capsule and tablets utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 29:195-201.